OptiTROP-Lung06:🫁
Sac-TMT + pembrolizumab improved median PFS in PD-L1–negative advanced nonsquamous NSCLC (15.0 vs 5.7 months; HR 0.49), with fewer grade 3 or higher adverse events. OS remains immature; follow-up is key.
@OncoAlert #ESMO26 #LungCancer #ESMOcommunity @myESMO
23 views · 5 likes · 2 reposts · 0 replies
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSymbiotic-GYN-18 (GOG-3145/ENGOT-EN37/APGOT-EN6/LACOG 0426-EVA): Phase 3 study of PF-08634456 in combination with pembrolizumab versus placebo plus pembrolizumab in participants with advanced or recurrent endometrial cancer
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgOriginal Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) https://nej.md/4Bo3liu #ESMO26 | @myESMO在 X 查看被引用的帖子
Source: Aya Mohamed | MSc, MD 🎗 · x.com